Activity of pazopanib in chemo-resistant patients with germ cell tumors (GCT): First results of the open-label, single-group, phase II PAZOTEST-01 trial

被引：2
|
作者：
Giannatempo, Patrizia
Nicolai, Nicola
Fare, Elena
Raggi, Daniele
Piva, Luigi
Biasoni, Davide
Catanzaro, Mario
Torelli, Tullio
Stagni, Silvia
Maffezzini, Massimo
Crestani, Alessandro
Togliardi, Elena
Salvioni, Roberto
Gianni, Alessandro M.
Necchi, Andrea
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[2] Natl Canc Istitute Milan, Milan, Italy
[3] Univ Milan, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.376
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
376
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PAZOPANIB IN CHEMORESISTANT PATIENTS WITH GERM CELL TUMORS (GCT): UPDATED RESULTS OF THE OPEN-LABEL, SINGLE-GROUP, PHASE 2 PAZOTEST-01 TRIAL
    Necchi, Andrea
    Giannaternpo, Patrizia
    Mariani, Luigi
    Nicolai, Nicola
    Fare, Elena
    Raggi, Daniele
    Piva, Luigi
    Biasoni, Davide
    Catanzaro, Mario
    Torelli, Tullio
    Stagni, Silvia
    Maffezzini, Massimo
    Togliardi, Elena
    Salvioni, Roberto
    De Braud, Filippo
    Gianni, Alessandro
    [J]. ANTICANCER RESEARCH, 2014, 34 (05) : 2661 - 2662
  • [2] Pazopanib in patients (pts) with advanced germ cell tumors (GCT): Results from an open-label, single-group, phase 2 trial (Pazotest-01).
    Necchi, Andrea
    Raggi, Daniele
    Giannatempo, Patrizia
    Calareso, Giuseppina
    Togliardi, Elena
    Nicolai, Nicola
    Crippa, Flavio
    Mariani, Luigi
    Salvioni, Roberto
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [3] Pazopanib in chemoresistant patients with germ cell tumors (GCT): Updated results of the open-label, single-group, phase 2 Pazotest-01 trial.
    Glennatempo, Patrizia
    Mariani, Luigi
    Nicolai, Nicola
    Fare, Elena
    Raggi, Daniele
    Maronglu, Manuals
    Plva, Luigi
    Blasonl, Davide
    Catanzaro, Mario
    Torelli, Tullio
    Stagni, Silvia
    Maffezzini, Massimo
    Togliardi, Elena
    Salvioni, Roberto
    De Braud, Filippo G.
    Gianni, Alessandro M.
    Necchi, Andrea
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Pazopanib (PZP) in germ cell tumors (GCT) after chemotherapy (CT) failure: Final results of the open label, single-group, phase II Pazotest trial.
    Necchi, Andrea
    Lo Vullo, Salvatore
    Giannatempo, Patrizia
    Raggi, Daniele
    Calareso, Giuseppina
    Togliardi, Elena
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [5] Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial
    Necchi, A.
    Lo Vullo, S.
    Giannatempo, P.
    Raggi, D.
    Calareso, G.
    Togliardi, E.
    Crippa, F.
    Pennati, M.
    Zaffaroni, N.
    Perrone, F.
    Busico, A.
    Colecchia, M.
    Nicolai, N.
    Mariani, L.
    Salvioni, R.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (06) : 1346 - 1351
  • [6] An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumors (GCT): Results at the end of first stage (FM12GCT01).
    Necchi, Andrea
    Magazzu, Domenico
    Anichini, Andrea
    Raggi, Daniele
    Giannatempo, Patrizia
    Nicolai, Nicola
    Colecchia, Maurizio
    Paolini, Biagio
    Coradeschi, Elisa
    Tassi, Elena
    Grazia, Giulia
    Mortarini, Roberta
    Calareso, Giuseppina
    Togliardi, Elena
    Crippa, Flavio
    Salvioni, Roberto
    Gianni, Alessandro M.
    Valagussa, Pinuccia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [7] An open-label, single-group, phase 2 study of Brentuximab Vedotin as salvage therapy for males with relapsed germ-cell tumors (GCT): results at the end of first stage (FM12GCT01)
    Necchi, A.
    Magazzu, D.
    Anichini, A.
    Raggi, D.
    Giannatempo, P.
    Colecchia, M.
    Coradeschi, E.
    Calareso, G.
    Togliardi, E.
    Crippa, F.
    Salvioni, R.
    Valagussa, P.
    [J]. BONE MARROW TRANSPLANTATION, 2016, 51 : S56 - S56
  • [8] Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
    Necchi, Andrea
    Mariani, Luigi
    Zaffaroni, Nadia
    Schwartz, Lawrence H.
    Giannatempo, Patrizia
    Crippa, Flavio
    Morosi, Carlo
    Lanocita, Rodolfo
    Sava, Teodoro
    Ortega, Cinzia
    Messina, Caterina
    Sacco, Cosimo
    Pennati, Marzia
    Daidone, Maria G.
    Nicolai, Nicola
    De Braud, Filippo
    Gianni, Alessandro M.
    Salvioni, Roberto
    [J]. LANCET ONCOLOGY, 2012, 13 (08): : 810 - 816
  • [9] An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors
    Oechsle, Karin
    Honecker, Friedemann
    Kollmannsberger, Christian
    Rick, Oliver
    Gruenwald, Victor
    Mayer, Frank
    Hartmann, Joerg T.
    Bokemeyer, Carsten
    [J]. ANTI-CANCER DRUGS, 2007, 18 (03) : 273 - 276
  • [10] An open-label, single-group, multicenter phase II study of lanreotide autogel (LAN) in Japanese patients (pts) with neuroendocrine tumors (NET).
    Ito, Tetsuhide
    Hisamatsu, Seiichi
    Nakajima, Akihiro
    Shimatsu, Akira
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
12345